GeneReach Biotechnology - Asset Resilience Ratio

Latest as of December 2025: 28.34%

GeneReach Biotechnology (4171) has an Asset Resilience Ratio of 28.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4171 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$249.69 Million

≈ $7.87 Million USD Cash + Short-term Investments

Total Assets

NT$881.05 Million

≈ $27.76 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how GeneReach Biotechnology's Asset Resilience Ratio has changed over time. See GeneReach Biotechnology (4171) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down GeneReach Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GeneReach Biotechnology (4171) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$249.69 Million	28.34%
Total Liquid Assets	NT$249.69 Million	28.34%

Asset Resilience Insights

Very High Liquidity: GeneReach Biotechnology maintains exceptional liquid asset reserves at 28.34% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

GeneReach Biotechnology Industry Peers by Asset Resilience Ratio

Compare GeneReach Biotechnology's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for GeneReach Biotechnology (2018–2025)

The table below shows the annual Asset Resilience Ratio data for GeneReach Biotechnology.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	28.34%	NT$249.69 Million ≈ $7.87 Million	NT$881.05 Million ≈ $27.76 Million	-8.56pp
2024-12-31	36.90%	NT$393.49 Million ≈ $12.40 Million	NT$1.07 Billion ≈ $33.60 Million	+10.11pp
2023-12-31	26.79%	NT$315.10 Million ≈ $9.93 Million	NT$1.18 Billion ≈ $37.05 Million	+25.84pp
2022-12-31	0.95%	NT$15.36 Million ≈ $483.77K	NT$1.62 Billion ≈ $51.10 Million	+0.13pp
2021-12-31	0.82%	NT$13.84 Million ≈ $436.04K	NT$1.68 Billion ≈ $53.07 Million	-2.62pp
2020-12-31	3.44%	NT$42.72 Million ≈ $1.35 Million	NT$1.24 Billion ≈ $39.08 Million	-30.26pp
2018-12-31	33.70%	NT$233.82 Million ≈ $7.37 Million	NT$693.83 Million ≈ $21.86 Million	--

pp = percentage points

About GeneReach Biotechnology

TWO:4171 Taiwan Biotechnology

Market Cap

$31.41 Million

NT$997.06 Million TWD

Market Cap Rank

#23649 Global

#1493 in Taiwan

Share Price

NT$17.40

Change (1 day)

-0.29%

52-Week Range

NT$16.95 - NT$26.50

All Time High

NT$246.40